Protara Therapeutics Inc 2025年季度报告

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of May 1, 2025 there were38,581,863shares of the registrant’s common stock, par value $0.001 per share, outstanding. TABLE OF CONTENTS CAUTIONARY NOTE CONCERNING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements, which reflect our current views with respect to, amongother things, our operations and financial performance. All statements other than statements of historical facts contained in thisQuarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify these forward-looking statements byterminology such as “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “seek,” “approximately,” “predict,” These forward-looking statements include, but are not limited to, statements about: ●estimates regarding our financial performance, including future revenue, expenses and capital requirements;●our expected cash position and ability to obtain financing in the future on satisfactory terms or at all;●expectations regarding our plans to research, develop and commercialize our current and future product candidates, includingTARA-002, and Intravenous, or IV, Choline Chloride;●expectations regarding the safety and efficacy of our product candidates;●expectations regarding the timing, costs and outcomes of our clinical trials;●expectations regarding potential market size;●expectations regarding the timing of the availability of data from our clinical trials;●expectations regarding the clinical utility, potential benefits and market acceptance of our product candidates;●expectations regarding our commercialization, marketing and manufacturing capabilities and strategy;●the implementation of our business model, strategic plans for our business, product candidates and technology;●expectations regarding our ability to identify additional products or product candidates with significant commercial potential;●developments and projections relating to our competitors and industry;●our ability to acquire, license and invest in businesses, technologies, product candidates and products;●our ability to remain listed on the Nasdaq Global Market, or Nasdaq;●the impact of government laws and regulations, including any executive orders or tariffs; ●costs and outcomes relating to any disputes, governmental inquiries or investigations, regulatory proceedings, legalproceedings or litigation; ●our ability to attract and retain key personnel to manage our business effectively;●our ability to prevent system failures, data breaches or violations of data protection laws;●the timing or likelihood of regulatory filings and approvals;●our ability to protect our intellectual property position; and ●the impact of general U.S., foreign and global economic, industry, market, regulatory, political or public health conditions. All forward-looking statements in this Quarterly Report on Form 10-Q are made as of the date of this document and involveknown and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to bematerially different from any future results, performance or achievements expressed or implied by these forward-looking statements.Factors that may cause actual results to differ materially from current expectations include, among other things, the risk factors setforth below in Part II, Item 1A,Risk Factors, and elsewhere in this Quarterly Report on Form 10-Q or in our other filings with theUnited States Securities and Exchange Commission, or the SEC. These factors should not be construed as exhaustive and should be This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, ourbusiness, and the markets for certain medical conditions, including data regarding the estimated size of those markets, and theincidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market researchor similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events PROTARA THERAPEUTICS, INC. AND SUBSIDIARIESUnaudited Condensed Consolidated Balance Sheets(in thousands, except share and per share data) Protara Therapeutics, Inc. and SubsidiariesNotes to Unaudited Condensed Consolidated Financial Statements(amounts in thousands, except share and per share data) 1. Organization and Nature of the Business Overview Protara Therapeutics, Inc., and its consolidated subsidiaries (“Protara” or the “Company”), is a clinical-stage biopharmaceuticalcompany committed to advancing transformative therapies for the treatment of cancer and rare diseases. Protara’s portfolio includestwo development programs utilizing TARA-002, an investigational cell therapy in development for the treatment of non-muscleinvasive blad